801282-00-8

Usage

Uses

Used in Organic Chemistry:
Benzenamine, 2-fluoro-3-methoxy(9CI) is used as a building block in the synthesis of various organic compounds. Its unique chemical structure allows for the formation of new compounds with different properties and applications.
Used in Pharmaceutical Industry:
Benzenamine, 2-fluoro-3-methoxy(9CI) may exhibit interesting biological activities, making it a valuable tool for drug discovery and development. Its presence in pharmaceutical compounds can potentially enhance their efficacy and selectivity.
Used in Materials Science:
The presence of the fluoro and methoxy groups in Benzenamine, 2-fluoro-3-methoxy(9CI) can impart specific physical and chemical properties to the compound. This makes it useful in the design and development of new materials with desired characteristics, such as improved stability, reactivity, or selectivity.

InChI:InChI=1/C7H8FNO/c1-10-6-4-2-3-5(9)7(6)8/h2-4H,9H2,1H3

Upstream product

• 137654-20-7 2-fluoro-3-methoxybenzoic acid 
• 801281-99-2 tert-butyl N-(2-fluoro-3-methoxyphenyl)carbamate 

Downstream Products

• 1073119-05-7 C₉H₁₀FNO₂ 
• 1272719-23-9 C₉H₅FN₂OS 
• 1272719-07-9 3-fluoro-4-[3-(4-fluoro-phenyl)-4,4-dimethyl-5-oxo-2-thioxo-imidazolidin-1-yl]-2-methoxy-benzonitrile 
• 1272719-08-0 4-[4,4-dimethyl-3-(6-methyl-pyridin-3-yl)-5-oxo-2-thioxo-imidazolidin-1-yl]-3-fluoro-2-methoxy-benzonitrile 
• 1272719-09-1 3-fluoro-4-[3-(4-methanesulfonyl-phenyl)-4,4-dimethyl-5-oxo-2-thioxo-imidazolidin-1-yl]-2-methoxy-benzonitrile 
• 1272719-10-4 4-[3-(4-cyano-2-fluoro-3-methoxy-phenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide 
• 1272719-11-5 4-(4,4-dimethyl-5-oxo-2-thioxo-3-p-tolyl-imidazolidin-1-yl)-3-fluoro-2-methoxy-benzonitrile 
• 1272719-12-6 3-fluoro-4-[3-(3-fluoro-4-methyl-phenyl)-4,4-dimethyl-5-oxo-2-thioxo-imidazolidin-1-yl]-2-methoxy-benzonitrile 
• 1272719-18-2 4-(4,4-dimethyl-5-oxo-2-thioxo-3-p-cyanophenyl-imidazolidin-1-yl)-3-fluoro-2-methoxy-benzonitrile 
• 1272719-20-6 C₉H₉BrFNO₂ 
• 1272719-21-7 C₁₀H₉FN₂O₂ 
• 1272719-22-8 C₈H₇FN₂O 
• 1186326-66-8 3-amino-2-fluorophenol 

Relevant academic research and scientific papers

ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF

Disclosed are substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds. The compounds and compositions can be used for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss and hypertrichosis.

ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF

The present invention relates to novel substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss, muscle loss, acne and hirsutism.

Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350

SAR analysis performed with a limited set of cyclopentane-containing macrocycles led to the identification of N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]- 13-methyl-2,14-dioxo-3,13-diazatricyclo [13.3.0.04,6]octadec-7-ene-4-carbonyl](cyclopropyl)sulfonamid e (TMC435350, 32c) as a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM). TMC435350 also displayed low in vitro clearance and high permeability, which were confirmed by in vivo pharmacokinetic studies. TMC435350 is currently being evaluated in the clinics.

SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN

The present invention provides a compound of formula (I): Y-J-NH-Z wherein: Y is a quinoline or isoquinoline optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; J is pyridine, pyridazine, pyrazine, pyrimidine or triazine optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C3-5cycloalkyl, C1-4alkoxy, hydroxyC1-4alkyl, cyano, hydroxy, C1-4cycloalkoxy, C1-4alkylthio, haloC1-4alkoxy, nitro, Q, (CH2)pQ, NR2R3, -(CH2)pNR2R3 and -O(CH2)pNR2R3; wherein J is substituted at positions meta to each other by NH and Y; and Z is phenyl or pyridyl optionally substituted with one or two substituents independently selected from halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; Q is phenyl, a five-membered heterocyclic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, or a six-membered heterocyclic ring containing one, two or three nitrogen atoms, optionally substituted by C1-4alkyl; each R2 and R3 is chosen from H and C1-4alkyl, or R2 and R3, together with the nitrogen atom to which they are attached, may form a six-membered ring optionally containing an oxygen atom or a further nitrogen atom, which ring is optionally substituted by C1-4alkyl or Q; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in methods of therapy; use of it for manufacturing medicaments; and methods of using it to treat diseases requiring administration of a VR1 antagonist such as pain, cough, GERD and depression.

HEPATITIS C INHIBITOR COMPOUNDS

Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.